Partner Headlines - NPSP

  1. NPS Pharma Initiates Phase 2a Study Of NPSP795 In Adult Patients ...

    Benzinga
  2. Valeant Goes For Allergan; Analyst Touts Shire Option

    IBD
  3. Mid-Afternoon Market Update: Markets Turn Back As SolarCity Hangs ...

    Benzinga
  4. Mid-Day Market Update: Keurig Green Mountain Jumps On Upbeat ...

    Benzinga
  5. Mid-Morning Market Update: Markets Gain; Wendy's Profit Beats ...

    Benzinga
  6. Morning Market Losers

    Benzinga
  7. UPDATE: Canaccord Genuity Assumes Coverage on NPS Pharmaceuticals ...

    Benzinga
  8. Benzinga's Top Initiations

    Benzinga
  9. UPDATE: Jefferies Downgrades NPS Pharmaceuticals on Valuation

    Benzinga
  10. NPS Pharma Finds Big Success In Tiny Markets

    IBD
  11. Market Wrap For January 8: Fed Minutes Released

    Benzinga
  12. NPS Pharmaceuticals Receives Orphan Drug Designation for Natpara ...

    Benzinga
  13. Catalyst Stock Plunge: Ugly In Orphan Drug Land

    YCharts
  14. Mid-Afternoon Market Update: Markets Mixed as Tesla Shares Remain ...

    Benzinga
  15. NPS Pharma Says Data from STEPS 2 Trial of Gattex Supports Long-Term ...

    Benzinga
  16. Mid-Afternoon Market Update: Markets Green as Spirit Airlines ...

    Benzinga
  17. Mid-Day Market Update: Micron Shares Tumble On Downbeat Profit; ...

    Benzinga
  18. Mid-Morning Market Update: Markets Rise; JPMorgan Posts Upbeat ...

    Benzinga
  19. Orphan Drugs: No (Payer) News Is Good News

    YCharts
  20. NPS Pharma Says 53% of Natpara-Treated Patients Achieved Primary ...

    Benzinga
  21. UPDATE: Bank of America Initiates Coverage on NPS Pharmaceuticals ...

    Benzinga
  22. Benzinga's Top Initiations

    Benzinga
  23. NPS Pharma Says sNDA Submitted for Gattex STEPS 2 Data, Shows ...

    Benzinga
  24. Weekly CFO Sells Highlight: WRES, NPSP, MKTO, GRPN, RXN

    GuruFocus
  25. UPDATE: J.P. Morgan Initiates Coverage on NPS Pharmaceuticals ...

    Benzinga
  26. Benzinga's Top Initiations

    Benzinga
  27. UPDATE: Oppenheimer Raises PT on NPS Pharmaceuticals Following ...

    Benzinga
  28. Market Wrap for Friday, August 9: Stocks Close Lower To End Week

    Benzinga
  29. NPS Pharmaceuticals Chief: Why 250k-a-Year Orphan Drug is Worth ...

    YCharts
  30. You Can Expect More Insider Trading in Pharma Stocks: Here's ...

    YCharts
  31. FDA Approves NPS Gattex for Injection for Some SBS Patients

    Benzinga
  32. NPS Pharma Shares Moving Lower Amid FDA Approval of Gattex

    Benzinga
  33. NPS Pharma Publishes Pivotal Phase 3 Study of Gattex in Short ...

    Benzinga
  34. NPS Pharmaceuticals Inc. Reports Operating Results (10-Q)

    GuruFocus
  35. Benzinga Mid-Afternoon Market Update

    Benzinga
  36. Benzinga Mid-Day Market Update

    Benzinga
  37. Benzinga Mid-Morning Market Update

    Benzinga
  38. UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT ...

    Benzinga
  39. FDA Advisory Committee Unanimously Recommends Approval of Gattex® ...

    Benzinga
  40. Benzinga Mid-Day Market Update

    Benzinga
  41. Benzinga Mid-Afternoon Market Update

    Benzinga
  42. Benzinga Mid-Morning Market Update

    Benzinga
  43. UPDATE: Morgan Stanley Initiates NPS Pharmaceuticals at Overweight ...

    Benzinga
  44. Benzinga's Top Pre-Market Gainers

    Benzinga
  45. NPS Pharma Expects to File Natpara BLA in Mid 2013

    Benzinga
  46. Revestive Receives European Marketing Authorization for the Treatment ...

    Benzinga
  47. NPS Pharma Says Gattex Meeting October 16th

    Benzinga
  48. Biotechs With Upcoming PDUFA Dates

    Benzinga
  49. NPS Pharmaceuticals (NPSP) Gains 10.8% as Short Bowel Drug Moves ...

    MarketIntelligenceCenter
  50. Social Media Outlook for Friday June 22 (DRI, NPSP, R, GS)

    Benzinga
  51. Benzinga's Top Pre-Market Gainers

    Benzinga
  52. NPS Pharmaceuticals Reports NatparaTM Phase 3 Results to be Presented ...

    Benzinga
  53. NPS Pharmaceuticals Inc. Reports Operating Results (10-K)

    GuruFocus
  54. Benzinga's Top Pre-Market Gainers

    Benzinga
  55. Notable Call Options Activity in NPS Pharmaceuticals

    Benzinga
  56. Put Volume Surges on Plunging NPS Pharmaceuticals

    SchaeffersResearch
Trading Center